Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.

Dow Jones

06/26

Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion.

Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.

Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027.

Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers.

"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences," said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release.

Write to Kit Norton at kit.norton@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 25, 2026 15:12 ET (19:12 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2646025388"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2646025388\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2646025388?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 03:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646025388","market":"sg","top_or_hot":-1,"title":"Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Bio-Techne surged Thursday after Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> announced it agreed to purchase the company for $11.3 billion. \n</p>\n<p>\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&amp;P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n</p>\n<p>\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n</p>\n<p>\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n</p>\n<p>\n  Write to Kit Norton at kit.norton@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 15:12 ET (19:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-26 03:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Bio-Techne surged Thursday after Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> announced it agreed to purchase the company for $11.3 billion. \n</p>\n<p>\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&amp;P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n</p>\n<p>\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n</p>\n<p>\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n</p>\n<p>\n  Write to Kit Norton at kit.norton@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 15:12 ET (19:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2646025388","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646025388","pubTimestamp":1782414720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion.Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","MKKGY":"Merck KGaA","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","TECH":"Bio-Techne","BK4585":"ETF&股票定投概念","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4588":"碎股","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4121":"生命科学工具和服务"},"translate_title":"Bio-techne是标普500的顶级股票。德国默克公司为该公司支付了24%的溢价。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.97,"MKKGY":1.91},"content_text":"Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion. \n\n\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n\n\nMerck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n\n\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n\n\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n\n\n  Write to Kit Norton at kit.norton@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2026 15:12 ET (19:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}